AUTHOR=Shi Mingchao , Chu Fengna , Zhu Feiqi , Zhu Jie 

TITLE=Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab

JOURNAL=Frontiers in Aging Neuroscience

VOLUME=Volume 14 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2022.870517

DOI=10.3389/fnagi.2022.870517

ISSN=1663-4365

ABSTRACT=Alzheimer´s disease (AD) is the most prevalent form of age-related dementia in the 
world and its main pathological features consist of amyloid-β (Aβ) plaque deposits and 
neurofibrillary tangles formed by hyperphosphorylated tau protein. So far, only a few 
AD treatments approved have been applied in clinic, but the effects of these drugs are 
limited only for partial symptomatic relief to AD patients and are unable to alter AD 
progression. Afterwards, all efforts for AD treatments with targeting the pathogenic 
factors were unsuccessful over past decades, which suggested that the parthenogenesis of 
AD is complex. Recently, disease-modifying therapies (DMTs) that can change the 
underlying pathophysiology of AD, with anti-Aβ monoclonal antibodies (mabs) (such 
as aducanumab, bapineuzumab, gantenerumab, solanezumab and lecanemab) have 
been developed successively and conducted in clinical trials basis on the theory that a 
systemic failure of cell-mediated Aβ clearance contributes to AD occurrence and 
progression. In the review, we summarize recent studies on the therapeutic effects and 
clinical trial results of these mabs in AD patients. Specifically, we focus on discussion 
of the impact of aducanumab and lecanemab on AD pathology and clinical profiles. 
The review provides a possible evidence for applying immunotherapy with anti-Aβ
mabs in AD and analyzes lessons learnt from these clinical trials in order to further in-depth study the therapeutic and adverse effects of these anti-Aβ mabs on AD.